Asia-Pacific Genital Warts Market, By Morphology (Cauliflower-Like, Smooth Papular, Keratotic, and Flat Warts), Type (Prevention, Diagnostics, Treatment), Cause (HPV 6, HPV 11, Others), Location (Vulva, Cervix Uteri, Urethra, Anus, Scrotum), Gender (Male and Female), Dosage (Cream, Gel, Ointment, Intramuscularly and Others), End-User (Hospitals, Diagnostic Centers, Surgical Centers, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Pharmacy Stores and Others) – Industry Trends and Forecast to 2030.
Asia-Pacific Genital Warts Market Analysis and Size
The prevalence of sexually transmitted diseases (STDs) and human papillomavirus infections, the rise in the female population, the awareness programs by healthcare organizations in India to inculcate awareness about the prevention of STDs are expected to drive the Asia-Pacific genital warts market. Moreover, the increase in clinical trials, rise in healthcare expenditure and strategic initiatives by market players, and huge market potential in developing countries bolsters the Asia-Pacific genital warts market growth in the forecast period of 2023-2030. However, the increased cost of treatment for genital warts, the side effects noticed while undergoing treatment for genital warts, and lack of patient awareness are the restraints that could hinder the growth of the Asia-Pacific genital warts market. The rise in product recalls associated with the vaccines and patient compliance regarding the use of vaccines are the restraints that could hinder the market growth.
Data Bridge Market Research analyses that the Asia-Pacific genital warts market which was USD 430.10 million in 2022, is expected to reach USD 616.14 million by 2030, and is expected to undergo a CAGR of 4.7% during the forecast period of 2023 to 2030. “Hospitals” dominates the end user segment of the Asia-Pacific genital warts market due to technological advancements in hospital and diagnostic centers for the treatment of genital warts and the presence of well-trained dermatologists for the diagnosis and treatment of genital warts to the growing demand for drug. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Asia-Pacific Genital Warts Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2014-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Morphology (Cauliflower-Like, Smooth Papular, Keratotic, and Flat Warts), Type (Prevention, Diagnostics, Treatment), Cause (HPV 6, HPV 11, Others), Location (Vulva, Cervix Uteri, Urethra, Anus, Scrotum), Gender (Male and Female), Dosage (Cream, Gel, Ointment, Intramuscularly and Others), End-User (Hospitals, Diagnostic Centers, Surgical Centers, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Pharmacy Stores and Others)
|
|
Countries Covered
|
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific
|
|
Market Players Covered
|
Abbott (U.S.), Sanofi (France), Perrigo Company PLC (Ireland), 3M (U.S.), Lee's Pharmaceutical Holdings Ltd. (China), Cassiopea (Italy), Glenmark Pharmaceuticals (India), Bausch Health (Canada), Novartis International AG (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
Genital warts are one of the most recurrent types of sexually transmitted infections. The human papillomavirus is the virus responsible for causing genital warts. People will get infected with at least one type of human papillomavirus (HPV) at some point during their lives. Genital warts affect most of the moist tissues in the genital areas of male and female patients.
Asia-Pacific Genital Warts Market Dynamics
Drivers
- Increase in the Incidence of STD diseases
The rise in incidence of STD diseases and availability of effective product of the companies involved in research and development of STD diagnostics accelerate the market growth. The rising disease burden is primarily driving the STD diagnostics industry, which results by a significant margin in the rise of STD diagnostics usage. According to the Global Progress Report 2021, the total number of new cases of HIV was 1.7 million in 2020. In addition, 156 million new cases of Trichomonas vaginalis infection, 128 million new cases of Chlamydia trachomatis infection, 82 million new cases of Neisseria gonorrhea, and 7.1 million new cases of Treponema pallidum were recorded in 2020. The number of new cases of HBV and HCV was around 1.5 million in 2019.
- Rise in Rapid and early Diagnosis of STDs
HIV continues to be a major public health issue, globally. The purpose of screening is to identify people in an apparently healthy population who are at higher risk of a health problem or a condition so that an early treatment or intervention can be provided and thereby reduce the incidence and mortality rate within the population. For instance, in March 2022, National Chlamydia Screening Program (NCSP) was organized in the U.K. The main aim of the program is to reduce the risk of untreated chlamydia infection. This program also focused on reducing the time to test results and treatment and re-testing after treatment
According to the United Nations, there were around 382 million old age people, aged 60 years or above, across the globe in 2017 and this number is expected 2.1 billion by 2050.
- Growing Awareness regarding the Disease and Treatment
Growing awareness levels amongst patients and physicians pertaining to the applications is presumed to be contributing toward market growth. The aforementioned factor is believed to boost the adoption for a wide range of products which is expected to boost Asia-Pacific genital warts market over the forecast period of 2023 to 2030. Thus, an increase in product approvals for addressing the high demand for diagnosis of STDs may contribute to the growth of respective consumables in the market.
Increase in patient awareness through education campaigns, and growing government initiatives are anticipated to drive market growth. The report published by the World Health Organization in November 2021, reported that more than 1.0 million sexually transmitted infections are acquired globally and most of them are asymptomatic.
Moreover, the demand for STD diagnostics is not only limited to developed countries but is also being witnessed in the developing countries which will further act as driver that will lead to the growth of the Genital warts market in the above mentioned projected timeframe.
Opportunity
- Rising number of Health Programs
The market for treatment of genital warts has opportunities due to rising number of health awareness campaigns and programs that have inspired individuals to take better care of their health and to be more aware of diseases that can be brought on by using various goods. In addition, expansion of medical facilities worldwide and financial commitments from both public and private sectors have enabled the market. Recurrence of warts increases the demand for treatment. Several treatments are available for warts. However, recurrences are common. Such increasing applications will create lucrative opportunities in the market, thereby supplementing the market growth.
Restraints/Challenges
- Low Diagnostic Rate due to Lack of Awareness
On the other hand, low diagnostic rate due to lack of awareness may hamper the Asia-Pacific market. The prevalence of warts is higher among the population; however, the diagnosis rate is low in patients. For instance, according to the Health Protection Report, in England in 2018, the rate of genital warts diagnosis among girls aged 15 to 17 years attending sexual health services decreased 92%, as compared to that in 2014. Moreover, existing treatment procedures are often painful or invasive, can have undesirable outcomes such as scarring or dyspigmentation, and often require repeat visits. This results in a decrease in the diagnostic rate, which in turn, is projected to challenge the genital warts market in the forecast period of 2023-2030.
This Asia-Pacific genital warts market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Asia-Pacific genital warts market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In April 2021, Teva Pharmaceuticals launched the first generic Absorica (isotretinoin) pills for adverse recalcitrant nodular acne genital warts. For individuals with strong facial plane genital warts, oral isotretinoin is a viable treatment selection
- Orgenesis Inc. completed the acquisition of Tamir Biotechnology, Inc. containing Ranpirnase, Tamir Bio’s broad spectrum antiviral platform
Asia-Pacific Genital Warts Market Scope
The Asia-Pacific genital warts market is segmented on the basis of morphology, type, cause, location, gender, dosage, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Morphology
- Cauliflower-Like
- Smooth Papular
- Keratotic
- Flat Warts
Type
- Prevention
- Diagnostics
- Treatment
Cause
- HPV 6
- HPV 11
- Others
Location
- Vulva
- Cervix Uteri
- Urethra
- Anus
- Scrotum
Gender
- Male
- Female
Dosage
- Cream
- Gel
- Ointment
- Intramuscularly
- Others
End User
- Hospitals
- Diagnostic Centers
- Surgical Centers
- Ambulatory Surgical Centers
- Others
Distribution Channel
- Direct Tender
- Pharmacy Stores
- Others
Asia-Pacific Genital Warts Market Analysis/Insights
The Asia-Pacific Genital Warts Market is analysed and market size insights and trends are provided by country, morphology, type, cause, location, gender, dosage, end-user and distribution channel as referenced above.
The countries covered in the Asia-Pacific genital warts market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, and Rest of Asia-Pacific.
China is expected to grow with the highest CAGR in the forecasted period of 2023 to 2030 in the Asia-Pacific's regions as the demand for genital warts products is increasing very rapidly with urbanization and laboratory automation for the diagnosis of genital warts. China is also one of the leading countries to inculcate genital warts market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The Asia-Pacific genital warts market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Asia-Pacific genital warts market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Asia-Pacific genital warts market. The data is available for historic period 2015-2020.
Competitive Landscape and Asia-Pacific Genital Warts Market Share Analysis
The Asia-Pacific genital warts market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Asia-Pacific genital warts market.
Some of the major players operating in the Asia-Pacific genital warts market are:
- Abbott (U.S.)
- Sanofi (France)
- Perrigo Company PLC (Ireland)
- 3M (U.S.)
- Lee's Pharmaceutical Holdings Ltd (China)
- Cassiopea (Italy)
- Glenmark Pharmaceuticals ( India)
- Bausch Health (Canada)
- Novartis International AG (Switzerland)
SKU-